Interleukin Genetics (ILIU) 0.1601 $ILIU
Interleukin Genetics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 16, 7:00AM CDT
Two Agreements Year to Date to Incorporate PerioPredict into Employee Benefit Plans
Interleukin Genetics Announces Conference Call to Discuss First Quarter 2016 Financial Results
GlobeNewswire - Tue May 10, 8:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Monday, May 16, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company's first quarter ended March 31, 2016 financial results.
Four Top Stocks to Watch on Wednesday May 4th 2016
ACCESSWIRE - Wed May 04, 11:03AM CDT
MIAMI, FL / ACCESSWIRE / May 4, 2016 / Tech Stock Insider is issuing a report on four stocks to watch. EBIO, LCLP, XGTI, and MJNA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks, subscribe to our newsletter at TechStockInsider.com.
EBIO: 2.57 (+0.34), XGTI: 0.15 (unch)
Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases
GlobeNewswire - Wed May 04, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin's IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.
EBIO: 2.57 (+0.34)
Interleukin Genetics Receives Notice of Allowance for United States Patent for PerioPredict(R) Genetic Risk Test
GlobeNewswire - Tue Apr 26, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced that it has received a notice of allowance for a patent by the United States Patent and Trademark Office (USPTO) for an application covering the Company's PerioPredict Genetic Risk Test. The application, entitled "Method for Determining Severity and Progression of Periodontal Disease," has allowed claims covering methods of determining a subject's genotype to ascertain their risk of developing severe periodontal disease and the treatment of those at risk to slow the progression of the disease.
PerioPredict(R) Genetic Risk Test Incorporated into Freedom Dental Plan
GlobeNewswire - Thu Apr 21, 7:03AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced it has signed an agreement with Reimbursement Specialists, Inc., a Comprehensive Benefit Administrators (CBA) company and leading provider of benefits management services, to include coverage for Interleukin's PerioPredict Genetic Risk Test as part of CBA's Freedom Dental Plan.
Interleukin Genetics Announces Clarification of Commercial Test Compliance
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced the results of discussions with the U.S. Food and Drug Administration (FDA) in response to an Untitled Letter issued by the FDA on November 4, 2015 and a meeting on February 3, 2016 with personnel within FDA's Office of In Vitro Diagnostics and Radiological Health (OIR) to discuss Interleukin's written response to OIR with respect to the Untitled Letter. Interleukin believes it has maintained a constructive relationship with the FDA over many years and is committed to maintaining regulatory compliance for all of its tests.
Interleukin Genetics Reports Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Thu Mar 17, 7:00AM CDT
Progress in Executing Commercial Plan Underscored by
Interleukin Genetics Appoints Global Clinical Advisory Board To Guide Enhanced Healthcare through Targeted Management of Systemic Inflammation
GlobeNewswire - Wed Mar 16, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases that reduce longevity and life quality, today announced the appointment of leading experts to its newly formed Clinical Advisory Board to advise the Company on clinical programs aimed at demonstrating the clinical and health economic benefits of targeted prevention and treatment of periodontitis, a common local inflammatory disease, in the management of several chronic diseases that affect widespread tissues and organs of the body.
Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Tue Mar 15, 8:48AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Thursday, March 17, 2016, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company's fourth quarter and year-end 2015 financial results.
Interleukin Genetics Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 4:25PM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal third quarter of 2015, ended September 30, 2015.
Interleukin Genetics Reports Second Quarter 2015 Financial Results
BusinessWire - Fri Aug 14, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal second quarter of 2015, ended June 30, 2015.
Interleukin Genetics Announces Conference Call to Discuss Second Quarter 2015 Financial Results
BusinessWire - Fri Aug 07, 6:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Friday, August 14, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company's second quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company's website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com.
Interleukin Genetics to Present at 2015 Marcum MicroCap Conference
BusinessWire - Tue May 19, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics, will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015, at 2:30 p.m. (ET) at the Grand Hyatt New York in New York City.
Interleukin Genetics Granted Key European Patent Covering Inherent Health(R) Weight Management Genetic Test
BusinessWire - Wed Apr 15, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that it has been granted a patent by the European Patent Office (EPO) covering the Company's Inherent Health(R) Weight Management Genetic Test. The granted patent, entitled "Genetic Markers for Weight Management and Methods of Use Thereof," has claims covering methods of determining a subject's metabolic genotype and methods for selecting an appropriate therapeutic/dietary regimen or lifestyle recommendation based on the subject's metabolic profile and susceptibility to adverse weight management issues. The European patent grants coverage of the Weight Management Genetic Test into 2029. Corresponding patents have been granted in major markets throughout the world including Eurasia, Japan, Mexico, Russia and New Zealand, and patent applications are pending in the U.S. and other major markets.
Interleukin Genetics Appoints Mark B. Carbeau as CEO
BusinessWire - Tue Apr 07, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced the appointment of Mark B. Carbeau as Chief Executive Officer and Director. Dr. Kenneth S. Kornman, DDS, PhD, who served as the President and CEO since August 2012, will continue to serve as President, Chief Scientific Officer and a Director.
Interleukin Genetics Collaborators Present Scientific Research Supporting Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting
GlobeNewswire - Wed Apr 01, 10:50AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced two late-breaking poster presentations supporting its Inherent Health(R) Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting taking place March 28 - April 1, 2015, in Boston.
Interleukin Genetics and Employee Benefit Consulting Group LLC Partner to Expand Awareness and Adoption of PerioPredict(R)
BusinessWire - Mon Mar 30, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) and Employee Benefit Consulting Group LLC (EBCG) announced today the signing of a collaboration agreement to help expand knowledge and potential coverage for Interleukin's novel genetic risk test, PerioPredict(R). PerioPredict(R) is an innovative, easy-to-use tool that identifies individuals with a higher risk of progressing to severe periodontal disease.
Interleukin Genetics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 16, 7:00AM CDT
Two Agreements Year to Date to Incorporate PerioPredict into Employee Benefit Plans
Interleukin Genetics Announces Conference Call to Discuss First Quarter 2016 Financial Results
GlobeNewswire - Tue May 10, 8:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Monday, May 16, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company's first quarter ended March 31, 2016 financial results.
Four Top Stocks to Watch on Wednesday May 4th 2016
ACCESSWIRE - Wed May 04, 11:03AM CDT
MIAMI, FL / ACCESSWIRE / May 4, 2016 / Tech Stock Insider is issuing a report on four stocks to watch. EBIO, LCLP, XGTI, and MJNA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks, subscribe to our newsletter at TechStockInsider.com.
EBIO: 2.57 (+0.34), XGTI: 0.15 (unch)
Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases
GlobeNewswire - Wed May 04, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin's IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.
EBIO: 2.57 (+0.34)
Interleukin Genetics Receives Notice of Allowance for United States Patent for PerioPredict(R) Genetic Risk Test
GlobeNewswire - Tue Apr 26, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced that it has received a notice of allowance for a patent by the United States Patent and Trademark Office (USPTO) for an application covering the Company's PerioPredict Genetic Risk Test. The application, entitled "Method for Determining Severity and Progression of Periodontal Disease," has allowed claims covering methods of determining a subject's genotype to ascertain their risk of developing severe periodontal disease and the treatment of those at risk to slow the progression of the disease.
PerioPredict(R) Genetic Risk Test Incorporated into Freedom Dental Plan
GlobeNewswire - Thu Apr 21, 7:03AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced it has signed an agreement with Reimbursement Specialists, Inc., a Comprehensive Benefit Administrators (CBA) company and leading provider of benefits management services, to include coverage for Interleukin's PerioPredict Genetic Risk Test as part of CBA's Freedom Dental Plan.
Interleukin Genetics Announces Clarification of Commercial Test Compliance
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced the results of discussions with the U.S. Food and Drug Administration (FDA) in response to an Untitled Letter issued by the FDA on November 4, 2015 and a meeting on February 3, 2016 with personnel within FDA's Office of In Vitro Diagnostics and Radiological Health (OIR) to discuss Interleukin's written response to OIR with respect to the Untitled Letter. Interleukin believes it has maintained a constructive relationship with the FDA over many years and is committed to maintaining regulatory compliance for all of its tests.
Interleukin Genetics Reports Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Thu Mar 17, 7:00AM CDT
Progress in Executing Commercial Plan Underscored by
Interleukin Genetics Appoints Global Clinical Advisory Board To Guide Enhanced Healthcare through Targeted Management of Systemic Inflammation
GlobeNewswire - Wed Mar 16, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases that reduce longevity and life quality, today announced the appointment of leading experts to its newly formed Clinical Advisory Board to advise the Company on clinical programs aimed at demonstrating the clinical and health economic benefits of targeted prevention and treatment of periodontitis, a common local inflammatory disease, in the management of several chronic diseases that affect widespread tissues and organs of the body.
Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Tue Mar 15, 8:48AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Thursday, March 17, 2016, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company's fourth quarter and year-end 2015 financial results.
Interleukin Genetics Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 4:25PM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal third quarter of 2015, ended September 30, 2015.
Interleukin Genetics Reports Second Quarter 2015 Financial Results
BusinessWire - Fri Aug 14, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal second quarter of 2015, ended June 30, 2015.
Interleukin Genetics Announces Conference Call to Discuss Second Quarter 2015 Financial Results
BusinessWire - Fri Aug 07, 6:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Friday, August 14, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company's second quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company's website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com.
Interleukin Genetics to Present at 2015 Marcum MicroCap Conference
BusinessWire - Tue May 19, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics, will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015, at 2:30 p.m. (ET) at the Grand Hyatt New York in New York City.
Interleukin Genetics Granted Key European Patent Covering Inherent Health(R) Weight Management Genetic Test
BusinessWire - Wed Apr 15, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that it has been granted a patent by the European Patent Office (EPO) covering the Company's Inherent Health(R) Weight Management Genetic Test. The granted patent, entitled "Genetic Markers for Weight Management and Methods of Use Thereof," has claims covering methods of determining a subject's metabolic genotype and methods for selecting an appropriate therapeutic/dietary regimen or lifestyle recommendation based on the subject's metabolic profile and susceptibility to adverse weight management issues. The European patent grants coverage of the Weight Management Genetic Test into 2029. Corresponding patents have been granted in major markets throughout the world including Eurasia, Japan, Mexico, Russia and New Zealand, and patent applications are pending in the U.S. and other major markets.
Interleukin Genetics Appoints Mark B. Carbeau as CEO
BusinessWire - Tue Apr 07, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced the appointment of Mark B. Carbeau as Chief Executive Officer and Director. Dr. Kenneth S. Kornman, DDS, PhD, who served as the President and CEO since August 2012, will continue to serve as President, Chief Scientific Officer and a Director.
Interleukin Genetics Collaborators Present Scientific Research Supporting Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting
GlobeNewswire - Wed Apr 01, 10:50AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced two late-breaking poster presentations supporting its Inherent Health(R) Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting taking place March 28 - April 1, 2015, in Boston.
Interleukin Genetics and Employee Benefit Consulting Group LLC Partner to Expand Awareness and Adoption of PerioPredict(R)
BusinessWire - Mon Mar 30, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) and Employee Benefit Consulting Group LLC (EBCG) announced today the signing of a collaboration agreement to help expand knowledge and potential coverage for Interleukin's novel genetic risk test, PerioPredict(R). PerioPredict(R) is an innovative, easy-to-use tool that identifies individuals with a higher risk of progressing to severe periodontal disease.
